CoChat

Pathogenesis of primary biliary cirrhosis

Open access
Jones, D E J · 2008 · Postgraduate Medical Journal
Cited by 115

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

rimary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that affects up to one in 700 women in western populations (female to male ratio is approximately 10 to 1, with the disease typically presenting over the age of 40 years). 1 2 PBC is characterised histologically by damage to, and eventual loss of, the biliary epithelial cells (BEC) lining small intrahepatic bile ducts.BEC loss is typically accompanied by a significant portal tract inflammatory infiltrate that is mixed in phenotype (T cells (CD4 and CD8, with the latter predominating in the periductal areas), B cells, macrophages, eosinophils and natural killer cells).3 4 Early descriptions of PBC emphasised the predominant role played by the progression of bile duct loss, accompanied by increasing portal tract and linking fibrosis leading to biliary cirrhosis, in the clinical expression of PBC, and described an aggressive and uniformly fatal condition.5 Increased awareness of the condition and, in particular, the availability of diagnostic tools such as serology has led to broader and earlier diagnosis.6 This has had the effect that we now recognise PBC far more frequently than was previously the case, and typically do so at an earlier stage in the disease process.Broadening of the diagnostic base has, in addition, led us to appreciate that there is a significant subgroup within the PBC population who have a low risk of disease progression and who are unlikely to develop end-stage liver disease during a normal lifetime (but who remain at risk of developing the often life-altering symptoms of the disease such as fatigue, which are seemingly unrelated to the severity of the underlying liver disease).2 7 8 The factors that determine individual risk of disease progression remain unclear, precluding us, at present, from targeting disease-modifying therapies at ''high-risk'' patients.Study of the pathogenesis of PBC has focused, until relatively recently, almost entirely on immunological aspects of the disease.9 PBC was one of the first conditions in which the presence of autoantibodies in the serum was identified, and was one of the first conditions in which the antigen specificity of this autoreactive response was characterised. 3 This led, quite naturally, to the view that PBC is an autoimmune disease.This led, again not unreasonably (but largely unsuccessfully), to a focus on developing and applying therapies aimed at modifying this increasingly well-characterised autoreactive immune response.More recently, however, the true complexities of the processes seemingly contributing to PBC pathogenesis have begun to be appreciated and the exclusively autoimmune disease model has been challenged. PATHOLOGICAL FACTORS IN PBC cPBC pathogenesis from an immune system perspective PBC is characterised immunologically by the breakdown of immune self-tolerance to highly conserved mitochondrial and nuclear antigens (table 1). 3 10-19 The first autoreactive responses to be characterised in PBC were the serum antibody responses directed at antigens present on the inner mitochondrial membrane (antimitochondrial antibodies; AMA).AMA, which are present, often at very high titre, in over 95% of patients, are directed at the members of the 2-oxoacid dehydroganese complex family of multi-enzyme complexes.These complexes, which all play important roles in mitochondrial energetics, share a common multicomponent, multidomain structure.The dominant autoantibody response in PBC is directed at pyruvate dehydrogenase complex (PDC), although reactivity is seen to a lesser extent to all other 2-oxoacid dehydroganese complex family members (table 1).Within PDC, reactivity is seen, in particular, to the dihydrolipoamide acetyltransferase (E2) and enzyme 3 binding protein (E3BP) components.Reactivity is seen to these two antigens alone in over 90% of PBC patients.It was appreciated from relatively early on that the antibodies reactive with these two enzymes are fully crossreactive and that they can block the function of both enzymes.The mechanistic explanation for these two, in retrospect key, observations is the reactivity seen to a highly conserved structural motif present within both PDC-E2 and E3BP, 11 which consists of the binding domain for a lipoic acid (LA) co-factor that plays an essential role in enzyme function.The

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2007.122150

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 115

Metadata

Authors
Jones, D. E. J.
Venue
Postgraduate Medical Journal
Published
2008-01-01
Volume
84
Issue
987
Pages
23-33
ISSN
  • 0032-5473 (ISSN-L)
  • 1469-0756
OpenAlex
W2114006962
Cited by
115
References
18
FWCI
5.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathogenesis of primary biliary cirrhosis. https://app.cochat.ai/papers/10.1136/gut.2007.122150
The paper
Jones, D. E. J. (2008). Pathogenesis of primary biliary cirrhosis. Postgraduate Medical Journal. https://doi.org/10.1136/gut.2007.122150

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.